Minimal residual disease monitoring by flow cytometry

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 4, 2003, Pages 599-612

  Vidriales, María B ^a   San Miguel, Jesús F ^a,b   Orfao, Alberto ^b,d   Coustan Smith, Elaine ^c   Campana, Dario ^c,e  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Flow cytometry; Immunophenotype; Minimal residual disease

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD CELL; BONE MARROW; CANCER PATIENT; CELL STRUCTURE; CLINICAL FEATURE; FLOW CYTOMETRY; HUMAN; LEUKEMIA CELL; METHODOLOGY; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; DIAGNOSTIC PROCEDURE; GENE EXPRESSION; IMMUNOPHENOTYPING; MORPHOLOGICAL TRAIT; SENSITIVITY AND SPECIFICITY;

EID: 0242521518     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00067-7     Document Type: Article

References (85)

1. Campana D & Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-1434.
2. Foroni L, Harrison CJ, Hoffbrand AV et al. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. British Journal of Haematology 1999; 105: 7-24.
3. Lo Coco F, Diverio D, Falini B et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12-22.
4. van Dongen JJ, Macintyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-I Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
5. Campana D & Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Baillière's Clinical Haematology 2002; 15: 1-19.
6. Szczepanski T, Orfao A, van der Velden VH et al. Minimal residual disease in leukaemia patients. Lancet Oncology 2001; 2: 409-417.
7. Yin JA, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002; 360: 160-162.
8. Campana D. Determination of minimal residual disease in leukemia patients. British Journal of Haematology 2003; 121: 823-838.
9. Lorenzana R, Coustan-Smith E, Antillon F et al. Simple methods for the rapid exchange of flow cytometric data between remote centers. Leukemia 1999; 14: 336-337.
10. Pui CH, Raimondi SC, Behm FG et al. Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia. Blood 1986; 68: 1306-1310.
11. Abshire TC, Buchanan GR, Jackson JF et al. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology group study. Leukemia 1992; 6: 357-362.
12. Macedo A, San Miguel JF, Vidriales MB et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. Journal of Clinical Pathology 1996; 49: 15-18.
13. Thomas X, Campos L, Archimbaud E et al. Surface marker expression in acute myeloid leukaemia at first relapse. British Journal of Haematology 1992; 81: 40-44.
14. van Wering ER, Beishuizen A, Roeffen ET et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1523-1533.
15. Chucrallah AE, Stass SA, Huh YO et al. Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. Cancer 1995; 76: 985-991.
16. Guglielmi C, Cordone I, Boecklin F et al. Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications. Leukemia 1997; 11: 1501-1507.
17. Oelschlagel U, Nowak R, Schaub A et al. Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia. Cytometry 2000; 42: 247-253.
18. Baer MR, Stewart CC, Dodge RK et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97: 3574-3580.
19. Tomova A & Babusikova O. Shifts in expression of immunological cell markers in relapsed acute leukemia. Neoplasma 2001; 48: 164-168.
20. Ciudad J, San Miguel JF, Lopez-Berges MC et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. Journal of Clinical Oncology 1998; 16: 3774-3781.
21. Coustan-Smith E, Behm FG, Sanchez J et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
22. Terstappen LW, Safford M, Konemann S et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1992; 6: 70-80.
23. Macedo A, Orfao A, Gonzalez M et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995; 9: 993-998.
24. Lucio P, Gaipa G, van Lochem EG et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-I concerted action investigation of minimal residual disease in acute leukemia: international standardization and clinical evaluation. Leukemia 2001; 15: 1185-1192.
25. Wells DA, Sale GE, Shulman HM et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. American Journal of Clinical Pathology 1998; 110: 84-94.
26. Ciudad J, San Miguel JF, Lopez-Berges MC et al. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. British Journal of Haematology 1999; 104: 695-705.
27. Lucio P, Parreira A, van den Beemd MW et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999; 13: 419-427.
28. + cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000; 14: 816-825.
29. + precursors in normal human adult bone marrow: implications for minimal residual disease detection. Haematologica 1998; 83: 1069-1075.
30. Dworzak MN, Fritsch G, Panzer-Grumayer ER et al. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance. Leukemia and Lymphoma 2000; 38: 295-308.
31. Sievers EL, Lange BJ, Alonzo TA et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective children's cancer group study of 252 acute myeloid leukemia patients. Blood 2002 101: 3398-3406.
32. + lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. Cytometry 1999; 38: 70-75.
33. + malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993; 7: 853-858.
34. Macedo A, Orfao A, Vidriales MB et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Annals of Hematology 1995; 70: 189-194.
35. Weir EG, Cowan K, LeBeau P et al. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13: 558-567.
36. Lamkin T, Brooks J, Annett G et al. Immunophenotypic differences between putative hematopoietic stem cells and childhood B-cell precursor acute lymphoblastic leukemia cells. Leukemia 1994; 8: 1871-1878.
37. Reading CL, Estey EH, Huh YO et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
38. Bradstock KF, Janossy G, Pizzolo G et al. Subpopulations of normal and leukemic human thymocytes: an analysis with the use of monoclonal antibodies. Journal of the National Cancer Institute 1980; 65: 33-42.
39. Bradstock KF, Janossy G, Tidman N et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leukemia Research 1981; 5: 301-309.
40. Bradstock KF, Papageorgiou ES, Janossy G et al. Detection of leukaemic lymphoblasts in CSF by immunofluorescence for terminal transferase. Lancet 1980; 1: 1144.
41. Hooijkaas H, Hahlen K, Adriaansen HJ et al. Terminal deoxynucleotidyl transferase (TdT)-positive cells in cerebrospinal fluid and development of overt CNS leukemia: a 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma. Blood 1989; 74: 416-422.
42. Chen JS, Coustan-Smith E, Suzuki T et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97: 2115-2120.
43. Gross HJ, Verwer B, Houck D et al. Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry 1993; 14: 519-526.
44. + hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. Cytometry 1998; 34: 128-142.
45. +/lineage-cells. Clinical and Experimental Immunology 1999; 118: 392-401.
46. Campana D & Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152.
47. Campana D, Coustan-Smith E & Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163-171.
48. Orfao A, Ciudad J, Lopez-Berges MC et al. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leukemia Lymphoma 1994; 13(supplement 1): 87-90.
49. Nowak R, Oelschlaegel U, Schuler U et al. Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Cytometry 1997; 30: 47-53.
50. San Miguel JF, Martinez A, Macedo A et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.
51. San Miguel JF, Ciudad J, Vidriales MB et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Critical Reviews Oncology Hematology 1999; 32: 175-185.
52. Coustan-Smith E, Sancho J, Behm FG et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-58.
53. Coustan-Smith E, Sancho J, Hancock ML et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
54. Pui CH, Campana D & Evans WE. Childhood acute lymphoblastic leukemia-current status and future perspectives. Lancet Oncology 2001; 2: 597-607.
55. Dworzak MN, Froschl G, Printz D et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958.
56. Coustan-Smith E, Sancho J, Hancock ML et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002; 100: 2399-2402.
57. van der Velden V, Jacobs DC, Wijkhuijs AJ et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002; 16: 1432-1436.
58. Cortes JE & Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer 1995; 76: 2393-2417.
59. Verma A & Stock W. Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Current Opinion Oncology 2001; 13: 14-20.
60. Hoelzer D & Gokbuget N. Treatment of lymphoblastic lymphoma in adults. Baillière's Clinical Haematology 2002; 15: 713-728.
61. Brisco J, Hughes E, Neoh SH et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996; 87: 5251-5256.
62. Radich J, Gehly G, Lee A et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 2602-2609.
63. Foroni L, Coyle LA, Papaioannou M et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11: 1732-1741.
64. Mitterbauer G, Nemeth P, Wacha S et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. British Journal of Haematology 1999; 106: 634-643.
65. Mortuza FY, Papaioannou M, Moreira IM et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology 2002; 20: 1094-1104.
66. Muñoz L, Lopez O, Martino R et al. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia. Haematologica 2000; 85: 704-710.
67. Sánchez J, Serrano J, Gomez P et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. British Journal of Haematology 2002; 116: 686-694.
68. Vidriales MB, Perez JJ, Lopez-Berges C et al. Minimal residual disease (MRD) in adolescent (> 14 years) and adult acute lymphoblastic leukaemias (ALL): early immunophenotypical evaluation has high clinical value. Blood 2003; 101: 4695-4700.
69. Krampera M, Vitale A, Vincenzi C et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. British Journal of Haematology 2003; 120: 74-79.
70. Neale GA, Coustan-Smith E, Pan Q et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 1221-1226.
71. Malec M, Bjorklund E, Soderhall S et al. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia 2001; 15: 716-727.
72. Cave H, van der Werff ten Bosch J, Suciu S et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. New England Journal of Medicine 1998; 339: 591-598.
73. van Dongen JJ, Seriu T, Panzer-Grumayer ER et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia. in childhood. Lancet 1998; 352: 1731-1738.
74. Krauter J, Wattjes MP, Nagel S et al. Real-time RT-PCR for the detection and quantification of AMLI/MTG8 fusion transcripts in t(8;21)-positive AML patients. British Journal of Haematology 1999; 107: 80-85.
75. Buonamici S, Ottaviani E, Testoni N et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443-449.
76. Campana D. Determination of minimal residual disease in leukemia patients. British Journal of Haematology 2003; 101 (12): 4695-4700.
77. Sievers EL, Lange BJ, Buckley JD et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. Journal of the National Cancer Institute 1996; 88: 1483-1488.
78. Adriaansen HJ, Jacobs BC, Kappers-Klunne MC et al. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 1993; 7: 472-481.
79. Drach J, Drach D, Glassl H et al. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13: 893-901.
80. Wormann B, Griesinger F & Innig G. Detection of residual leukemic cells in patients with acute myeloid leukemia based on cell surface antigen expression. Sangre 1992; 37(supplement 3): 133-135.
81. Venditti A, Buccisano F, Del Poeta G et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952.
82. + cells for the detection of minimal residual disease in adult acute myeloid leukaemia. British Journal of Haematology 2000; 108: 710-716.
83. Muñoz L, Nomdedeu JF, Villamor N et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003; 17: 76-82.
84. San Miguel JF, Vidriales MB, Lopez-Berges C et al. Early immunophenotypical evaluation of minimal residual disease in acute myelold leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746-1751.
85. Sanz MA, Lo Coco F, Martin G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.